Diffusion Pharmaceuticals Inc. - FORM 10-K - EX-23.1 - EXHIBIT 23.1 - March 25, 2016

Attached files

file filename
10-K - FORM 10-K - Diffusion Pharmaceuticals Inc.dffn20151231_10k.htm
EX-3.3 - EXHIBIT 3.3 - Diffusion Pharmaceuticals Inc.ex3-3.htm
EX-4.7 - EXHIBIT 4.7 - Diffusion Pharmaceuticals Inc.ex4-7.htm
EX-3.4 - EXHIBIT 3.4 - Diffusion Pharmaceuticals Inc.ex3-4.htm
EX-21.1 - EXHIBIT 21.1 - Diffusion Pharmaceuticals Inc.ex21-1.htm
EX-31.2 - EXHIBIT 31.2 - Diffusion Pharmaceuticals Inc.ex31-2.htm
EX-10.3 - EXHIBIT 10.3 - Diffusion Pharmaceuticals Inc.ex10-3.htm
EX-31.1 - EXHIBIT 31.1 - Diffusion Pharmaceuticals Inc.ex31-1.htm
EX-10.24 - EXHIBIT 10.24 - Diffusion Pharmaceuticals Inc.ex10-24.htm
EX-32.2 - EXHIBIT 32.2 - Diffusion Pharmaceuticals Inc.ex32-2.htm
EX-32.1 - EXHIBIT 32.1 - Diffusion Pharmaceuticals Inc.ex32-1.htm

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in Registration Statement Nos. 333-206408 and 333-206409 on Form S-8 of our report dated March 25, 2016 relating to the financial statements of Diffusion Pharmaceuticals Inc. (formerly known as RestorGenex Corporation) (which report expresses an unqualified opinion and includes explanatory paragraphs relating to the ability of Diffusion Pharmaceuticals Inc. to continue as a going concern and the acquisition via merger of Diffusion Pharmaceuticals LLC in January 2016) appearing in this Annual Report on Form 10-K of Diffusion Pharmaceuticals Inc. for the year ended December 31, 2015.

 

/s/ Deloitte & Touche LLP

 

Chicago, Illinois

March 25, 2016

 

Diffusion Pharmaceuticals Inc. Reports